Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA

Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418

Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis

Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O’Riordan, C. R., & Smith, A. E. (1990) · Cell · doi:10.1016/0092-8674(90)90148-8 · Cited by 1,792

Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive

Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., & Welsh, M. J. (1992) · Nature · doi:10.1038/358761a0 · Cited by 1,236

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Goor, F. V., Hadidaꝉ, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A. K., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,225

Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report

Farrell, P. M., Rosenstein, B. J., White, T. B., Accurso, F. J., Castellani, C., Cutting, G. R., Durie, P. R., LeGrys, V. A., Massie, J., Parad, R. B., et al. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.05.005 · Cited by 1,093

Cystic fibrosis: A worldwide analysis ofCFTR mutations?correlation with incidence data and application to screening

Bobadilla, J. L., Macek, M., Fine, J. P., & Farrell, P. M. (2002) · Human Mutation · doi:10.1002/humu.10041 · Cited by 1,032

Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- CFTR Mutation

Accurso, F. J., Rowe, S. M., Clancy, J. P., Boyle, M., Dunitz, J., Durie, P. R., Sagel, S. D., Hornick, D. B., Konstan, M. W., Donaldson, S. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909825 · Cited by 803

Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation

Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Jallat, S., Dott, K., Dreyer, D., Crystal, R. G., Pavirani, A., Lecocq, J.-P., et al. (1991) · Nature · doi:10.1038/354526a0 · Cited by 707

Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice

Castellani, C., Cuppens, H., Maçek, M., Cassiman, J. J., Kerem, E., Durie, P. R., Tullis, E. D., Assael, B. M., Bombieri, C., Brown, A., et al. (2008) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.03.009 · Cited by 624

Small-molecule correctors of defective F508-CFTR cellular processing identified by high-throughput screening

Pedemonte, N. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24898 · Cited by 551

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitylation as a Novel Pharmaceutical Target for Cystic Fibrosis

Fukuda, R., & Okiyoneda, T. (2020) · Pharmaceuticals · doi:10.3390/ph13040075 · Cited by 23

Cystic Fibrosis Lung Disease in the Aging Population

Künzi, L., Easter, M., Hirsch, M. J., & Krick, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.601438 · Cited by 26

An Adverse Outcome Pathway for Decreased Lung Function Focusing on Mechanisms of Impaired Mucociliary Clearance Following Inhalation Exposure

Luettich, K., Sharma, M., Yepiskoposyan, H., Breheny, D., & Lowe, F. (2021) · Frontiers in Toxicology · doi:10.3389/ftox.2021.750254 · Cited by 23

SARS-CoV-2-Mediated Lung Edema and Replication Are Diminished by Cystic Fibrosis Transmembrane Conductance Regulator Modulators

Honrubia, J. M., Gutierrez-Alvarez, F. J., Sanz‐Bravo, A., González-Miranda, E., Muñoz‐Santos, D., Castaño-Rodríguez, C., Wang, L., Villarejo-Torres, M., Ripoll-Gómez, J., Esteban, A., et al. (2023) · mBio · doi:10.1128/mbio.03136-22 · Cited by 23

Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment

Hull, J. (2012) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2012.12s001 · Cited by 25

Advances in the Diagnosis and Treatment of Cystic Fibrosis

Martiniano, S. L., Hoppe, J. E., Sagel, S. D., & Zemanick, E. T. (2014) · Advances in Pediatrics · doi:10.1016/j.yapd.2014.03.002 · Cited by 25

Corrector-mediated rescue of misprocessed CFTR mutants can be reduced by the P-glycoprotein drug pump

Loo, T. W., Bartlett, M. C., Shi, L., & Clarke, D. M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.11.014 · Cited by 23

Novel Amino-Carbonitrile-Pyrazole Identified in a Small Molecule Screen Activates Wild-Type and ∆F508 Cystic Fibrosis Transmembrane Conductance Regulator in the Absence of a cAMP Agonist

Namkung, W., Park, J., Seo, Y., & Verkman, A. S. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.086348 · Cited by 23

Stem cell‐derived organoids to model gastrointestinal facets of cystic fibrosis

Hohwieler, M., Perkhofer, L., Liebau, S., Seufferlein, T. T. W., Müller, M., Illing, A., & Kleger, A. (2016) · United European Gastroenterology Journal · doi:10.1177/2050640616670565 · Cited by 22

Ligand-promoted protein folding by biased kinetic partitioning

Hingorani, K. S., Metcalf, M. C., Deming, D., Garman, S. C., Powers, E. T., & Gierasch, L. M. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2303 · Cited by 23

Concentration of fractional excretion of nitric oxide (FENO): A potential airway biomarker of restored CFTR function

Kotha, K. S., Szczesniak, R. D., Naren, A. P., Fenchel, M. C., Duan, L. L., McPhail, G. L., & Clancy, J. P. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.07.002 · Cited by 25

Translational research to enable personalized treatment of cystic fibrosis

Hagemeijer, M. C., Siegwart, D. J., Strug, L. J., Cebotaru, L., Torres, M. J., Sofoluwe, A., & Beekman, J. M. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.10.017 · Cited by 22

In utero and postnatal ivacaftor/lumacaftor therapy rescues multiorgan disease in CFTR-F508del ferrets

Evans, I. A., Sun, X., Liang, B., Vegter, A. R., Guo, L., Lynch, T. J., Zhang, Y., Zhang, Y., Yi, Y., Yu, Y., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.157229 · Cited by 22

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor

Tümmler, B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1158207 · Cited by 22

The low PLC-δ1 expression in cystic fibrosis bronchial epithelial cells induces upregulation of TRPV6 channel activity

Vachel, L., Norez, C., Jayle, C., Becq, F., & Vandebrouck, C. (2014) · Cell Calcium · doi:10.1016/j.ceca.2014.11.005 · Cited by 22

Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction

Brewington, J. J., McPhail, G. L., & Clancy, J. P. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1122527 · Cited by 24

Transformative therapies for rare CFTR missense alleles

Oliver, K. E., Han, S. T., Sorscher, E. J., & Cutting, G. R. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.09.018 · Cited by 23

A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators

Ponzano, S., Nigrelli, G., Fregonese, L., Eichler, I., Bertozzi, F., Bandiera, T., Galietta, L. J. V., & Papaluca, M. (2018) · European Respiratory Review · doi:10.1183/16000617.0124-2017 · Cited by 23

Pharmacological reversal of renal cysts from secretion to absorption suggests a potential therapeutic strategy for managing autosomal dominant polycystic kidney disease

Yanda, M. K., Cha, B., Cebotaru, C. V., & Cebotaru, L. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010320 · Cited by 22

Repeat dosing of AAV2. 5T to ferret lungs elicits an antibody response that diminishes transduction in an age-dependent manner

Tang, Y., Yan, Z., Lin, S., Huntemann, E. D., Feng, Z., Park, S.-Y., Sun, X., Yuen, E., & Engelhardt, J. F. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.008 · Cited by 21

Guanylate cyclase 2C agonism corrects CFTR mutants

Arora, K., Huang, Y., Mun, K., Yarlagadda, S., Sundaram, N., Kessler, M. M., Hannig, G., Kurtz, C. B., Silos‐Santiago, I., Helmrath, M. A., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93686 · Cited by 20

Multitarget CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach

Tassini, S., Langron, E., Delang, L., Mirabelli, C., Lanko, K., Crespan, E., Kiššová, M., Tagliavini, G., Fontò, G., Bertoni, S., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01416 · Cited by 21

CFTR: New insights into structure and function and implications for modulation by small molecules

Kleizen, B., Hunt, J. F., Callebaut, I., Hwang, T., Sermet‐Gaudelus, I., Hafkemeyer, S., & Sheppard, D. N. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.10.021 · Cited by 22

Role of Protein Kinase A-Mediated Phosphorylation in CFTR Channel Activity Regulation

Sala, A. D., Prono, G., Hirsch, E., & Ghigo, A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.690247 · Cited by 21

Long-Term Outcomes in Real Life of Lumacaftor–Ivacaftor Treatment in Adolescents With Cystic Fibrosis

Bui, S., Masson, A., Enaud, R., Roditis, L., Dournes, G., Galodé, F., Collet, C., Mas, E., Languepin, J., Fayon, M. J., et al. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.744705 · Cited by 21

Cystic fibrosis — What are the prospects for a cure?

Kumar, S., Tana, A., & Shankar, A. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.09.018 · Cited by 24

Bithiazole Correctors Rescue CFTR Mutants by Two Different Mechanisms

Loo, T. W., Bartlett, M. C., & Clarke, D. M. (2013) · Biochemistry · doi:10.1021/bi4008758 · Cited by 21

Blocking protein quality control to counter hereditary cancers

Kampmeyer, C., Nielsen, S. V., Clausen, L., Stein, A., Gerdes, A., Lindorff‐Larsen, K., & Hartmann‐Petersen, R. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22487 · Cited by 21

Unraveling the Function of Lemur Tyrosine Kinase 2 Network

Cruz, D. F., Farinha, C. M., & Swiatecka‐Urban, A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00024 · Cited by 21

Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease

Tong, K., Barker, D., France, M. W., Burr, L. D., Greville, H. W., Visser, S. K., Middleton, P. G., Wainwright, C. E., Dorahy, D. J., & Wark, P. A. B. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.12.006 · Cited by 21

Accumulation and persistence of ivacaftor in airway epithelia with prolonged treatment

Lee, T. N. G., Cholon, D. M., Quinney, N. L., Gentzsch, M., & Esther, C. R. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2020.04.010 · Cited by 21

Inhibition of Pseudomonas aeruginosa Alginate Synthesis by Ebselen Oxide and Its Analogues

Kim, S.-K., Ngo, H., Dennis, E. K., Chandrika, N. T., DeShong, P. R., Garneau‐Tsodikova, S., & Lee, V. T. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00045 · Cited by 23

Automated acquisition and analysis of airway surface liquid height by confocal microscopy

Choi, H.-C., Kim, C. S. K., & Tarran, R. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00027.2015 · Cited by 21

Different SUMO paralogues determine the fate of wild-type and mutant CFTRs: biogenesis versus degradation

Gong, X., Liao, Y., Ahner, A., Larsen, M. B., Wang, X., Bertrand, C. A., & Frizzell, R. A. (2018) · Molecular Biology of the Cell · doi:10.1091/mbc.e18-04-0252 · Cited by 21

The future of CFTR modulating therapies for cystic fibrosis

Davies, J. C. (2015) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000211 · Cited by 20

Chronic β2AR stimulation limits CFTR activation in human airway epithelia

Brewington, J. J., Backstrom, J., Feldman, A., Kramer, E. L., Moncivaiz, J. D., Ostmann, A. J., Zhu, X., Lu, L. J., & Clancy, J. P. (2018) · JCI Insight · doi:10.1172/jci.insight.93029 · Cited by 22

A small molecule CFTR potentiator restores ATP‐dependent channel gating to the cystic fibrosis mutant G551D‐CFTR

Liu, J., Berg, A. P., Wang, Y., Jantarajit, W., Sutcliffe, K. J., Stevens, E. B., Cao, L., Pregel, M. J., & Sheppard, D. N. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15709 · Cited by 20

Structural Comparative Modeling of Multi-Domain F508del CFTR

McDonald, E. F., Woods, H., Smith, S. T., Kim, M., Schoeder, C. T., Plate, L., & Meiler, J. (2022) · Biomolecules · doi:10.3390/biom12030471 · Cited by 19

Validating organoid-derived human intestinal monolayers for personalized therapy in cystic fibrosis

Birimberg‐Schwartz, L., Ip, W., Bartlett, C., Avolio, J., Vonk, A. M., Gunawardena, T. N. A., Du, K., Esmaeili, M., Beekman, J. M., Rommens, J. M., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202201857 · Cited by 20

Olive Leaf Extract (OLE) as a Novel Antioxidant That Ameliorates the Inflammatory Response in Cystic Fibrosis

Allegretta, C., Difonzo, G., Caponio, F., Tamma, G., & Laselva, O. (2023) · Cells · doi:10.3390/cells12131764 · Cited by 20

Delivering a New Future for People With Cystic Fibrosis

Burgener, E. B., & Cornfield, D. N. (2023) · PEDIATRICS · doi:10.1542/peds.2023-062985 · Cited by 21

Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates for cystic fibrosis

Liu, Z., Borlak, J. T., & Tong, W. (2014) · Genome Medicine · doi:10.1186/s13073-014-0094-2 · Cited by 20

New use for an old drug: COX‐independent anti‐inflammatory effects of sulindac in models of cystic fibrosis

Rocca, J., Manin, S., Lesne-Hulin, A., Aissat, A., Verbecq‐Morlot, W., Prulière-Escabasse, V., Wohlhuter‐Haddad, A., Epaud, R., Fanen, P., & Tarze, A. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13464 · Cited by 20

The proteome speciation of an immortalized cystic fibrosis cell line: New perspectives on the pathophysiology of the disease

Puglia, M., Landi, C., Gagliardi, A., Breslin, L., Armini, A., Brunetti, J., Pini, A., Bianchi, L., & Bini, L. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2017.09.013 · Cited by 20

Advances in the Diagnosis and Management of Cystic Fibrosis in the Genomic Era

Wiencek, J. R., & Lo, S. F. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.274670 · Cited by 23

High-Throughput Surface Liquid Absorption and Secretion Assays to Identify F508del CFTR Correctors Using Patient Primary Airway Epithelial Cultures

Berg, A. P., Hallowell, S., Tibbetts, M., Beasley, C., Brown-Phillips, T., Healy, A., Pustilnik, L. R., Doyonnas, R., & Pregel, M. J. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219849375 · Cited by 20

Inhibition of calpain 1 restores plasma membrane stability to pharmacologically rescued Phe508del-CFTR variant

Matos, A. M., Pinto, F. R., Barros, P., Amaral, M. D., Pepperkok, R., & Matos, P. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008738 · Cited by 21

Lipid-driven CFTR clustering is impaired in cystic fibrosis and restored by corrector drugs

Abu‐Arish, A., Pandžić, E., Luo, Y., Sato, Y., Turner, M. J., Wiseman, P. W., & Hanrahan, J. W. (2022) · Journal of Cell Science · doi:10.1242/jcs.259002 · Cited by 20

Transcomplementation by a Truncation Mutant of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Enhances ΔF508 Processing through a Biomolecular Interaction

Cebotaru, L., Woodward, O. M., Cebotaru, V., & Guggino, W. B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.420489 · Cited by 20

Pharmacological rescue of mutant CFTR protein improves the viscoelastic properties of CF mucus

Gianotti, A., Capurro, V., Scudieri, P., Galietta, L. J. V., Morán, Ó., & Zegarra‐Moran, O. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.11.003 · Cited by 21

Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosis‐causing mutation

Laselva, O., Erwood, S., Du, K., Ivakine, E. A., & Bear, C. E. (2019) · FASEB BioAdvances · doi:10.1096/fba.2019-00039 · Cited by 19

Precision Medicine Based on CFTR Genotype for People with Cystic Fibrosis

Haq, I., Almulhem, M. M., Soars, S., Poulton, D., & Brodlie, M. (2022) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s245603 · Cited by 20

Ocular development after highly effective modulator treatment early in life

Zhu, Y., Li, D., Reyes‐Ortega, F., Chinnery, H. R., & Schneider‐Futschik, E. K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1265138 · Cited by 19

Functional Rescue of a Kidney Anion Exchanger 1 Trafficking Mutant in Renal Epithelial Cells

Chu, C., King, J. C., Berrini, M., Alexander, R. T., & Cordat, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057062 · Cited by 19

Partial rescue of F508del‐cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual‐acting small molecule

Liu, J., Bihler, H. J., Farinha, C. M., Awatade, N. T., Romão, A. M., Mercadante, D. L., Cheng, Y., Musisi, I., Jantarajit, W., Wang, Y., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14141 · Cited by 19

Investigating Potassium Channels in Budding Yeast: A Genetic Sandbox.

Mackie, T. D., & Brodsky, J. L. (2018) · PubMed Central · doi:10.1534/genetics.118.301026 · Cited by 19

CK19 stabilizes CFTR at the cell surface by limiting its endocytic pathway degradation

Hou, X., Wu, Q., Rajagopalan, C., Zhang, C., Bouhamdan, M., Wei, H., Chen, X., Zaman, K., Li, C., Sun, X., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201901050r · Cited by 18

CFTR transmembrane segments are impaired in their conformational adaptability by a pathogenic loop mutation and dynamically stabilized by Lumacaftor

Krainer, G., Schenkel, M., Hartmann, A. J., Ravamehr-Lake, D., Deber, C. M., & Schlierf, M. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ac119.011360 · Cited by 19

Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease

Strub, M. D., & McCray, P. B. (2020) · Genes · doi:10.3390/genes11050546 · Cited by 19

Correctors modify the bicarbonate permeability of F508del-CFTR

Fiore, M., Picco, C., & Morán, Ó. (2020) · Scientific Reports · doi:10.1038/s41598-020-65287-4 · Cited by 19

Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study

Donaldson, S. H., Laube, B. L., Mogayzel, P. J., Corcoran, T. E., Pilewski, J. M., Ceppe, A., Wu, J., Bhambhvani, P. G., Ratjen, F. A., Sagel, S. D., et al. (2021) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2021.05.004 · Cited by 19

Another Beginning for Cystic Fibrosis Therapy

Davis, P. B. (2015) · New England Journal of Medicine · doi:10.1056/nejme1504059 · Cited by 21

Rationale and design of the HIT-CF organoid study: stratifying cystic fibrosis patients based on intestinal organoid response to different CFTR-modulators

van Mourik, P., Heida-Michel, S., Vonk, A. M., Beekman, J. M., van der Ent, C. K., DeKeyser, H., Lammertyn, E. J., Koningsbruggen-Rietschel, S. V., Naehrlich, L., Pool, J., et al. (2020) · Translational Medicine Communications · doi:10.1186/s41231-020-00060-3 · Cited by 19

Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cardiorespiratory Polygraphy Parameters and Respiratory Muscle Strength in Cystic Fibrosis Patients with Severe Lung Disease

Giallongo, A., Parisi, G. F., Papale, M. R., Manti, S., Mulè, E., Aloisio, D., Terlizzi, V., Rotolo, N., & Leonardi, S. (2023) · Genes · doi:10.3390/genes14020449 · Cited by 20

The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold?

Oliver, K. E., Carlon, M. S., Pedemonte, N., & Lopes‐Pacheco, M. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2230129 · Cited by 19

Innovative Strategy toward Mutant CFTR Rescue in Cystic Fibrosis: Design and Synthesis of Thiadiazole Inhibitors of the E3 Ligase RNF5

Brusa, I., Sondo, E., Pesce, E., Tomati, V., Gioia, D., Falchi, F., Balboni, B., Martínez, J. A. O., Veronesi, M., Romeo, E., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00608 · Cited by 19

Identification of α-Tocopherol succinate as an RFFL-substrate interaction inhibitor inducing peripheral CFTR stabilization and apoptosis

Taniguchi, S., Ono, Y., Doi, Y., Taniguchi, S., Matsuura, Y., Iwasaki, A., Hirata, N., Fukuda, R., Inoue, K., Yamaguchi, M., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115730 · Cited by 19

Reduced PDZ Interactions of Rescued ΔF508CFTR Increases Its Cell Surface Mobility

Valentine, C. D., Lukács, G. L., Verkman, A. S., & Haggie, P. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421172 · Cited by 20

Electrophysiological evaluation of Cystic Fibrosis Conductance Transmembrane Regulator (CFTR) expression in human monocytes

Ettorre, M., Verzè, G., Caldrer, S., Johansson, J., Calcaterra, E., Assael, B. M., Melotti, P., Sorio, C., & Buffelli, M. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.07.010 · Cited by 18

Pharmacological Chaperones: Beyond Conformational Disorders

Leidenheimer, N. J. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_68 · Cited by 19

Lumacaftor-rescued F508del-CFTR has a modified bicarbonate permeability

Ferrera, L., Baroni, D., & Morán, Ó. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.01.012 · Cited by 18

Re-imagining cystic fibrosis care: next generation thinking

Rang, C., Keating, D., Wilson, J. W., & Kotsimbos, T. C. (2020) · European Respiratory Journal · doi:10.1183/13993003.02443-2019 · Cited by 18

The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants

Turner, M. J., Luo, Y., Thomas, D. Y., & Hanrahan, J. W. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00285.2019 · Cited by 18

A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation

McKone, E. F., DiMango, E., Sutharsan, S., Barto, T. L., Campbell, D., Ahluwalia, N., Higgins, M., Owen, C. A., & Tullis, E. D. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2020.11.003 · Cited by 19

Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?

Edmondson, C. L., Course, C. W., & Doull, I. J. M. (2021) · Archives of Disease in Childhood · doi:10.1136/archdischild-2020-320680 · Cited by 19

Molecular Dynamics and Theratyping in Airway and Gut Organoids Reveal R352Q-CFTR Conductance Defect

Wong, S. L., Awatade, N. T., Astore, M. A., Allan, K. M., Carnell, M. J., Šlapetová, I., Chen, P., Setiadi, J., Pandzic, E., Fawcett, L. K., et al. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0337oc · Cited by 15

Repairing mutated proteins – development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator

Merk, D., & Schubert‐Zsilavecz, M. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.788495 · Cited by 19

Tissue-specific control of CFTR endocytosis by Dab2

Madden, D. R., & Swiatecka‐Urban, A. (2012) · Communicative & Integrative Biology · doi:10.4161/cib.21375 · Cited by 18

Improved fluorescence assays to measure the defects associated with F508del‐CFTR allow identification of new active compounds

Langron, E., Simone, M. I., Delalande, C., Reymond, J., Selwood, D. L., & Vergani, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13715 · Cited by 15

Vardenafil reduces macrophage pro-inflammatory overresponses in cystic fibrosis through PDE5- and CFTR-dependent mechanisms

Noël, S., Panin, N., Beka, M., Dhooghe, B., Huaux, F., & Leal, T. (2017) · Clinical Science · doi:10.1042/cs20160749 · Cited by 18

Hsp104 facilitates the endoplasmic‐reticulum–associated degradation of disease‐associated and aggregation‐prone substrates

Doonan, L. M., Guerriero, C. J., Preston, G. M., Buck, T. M., Khazanov, N., Fisher, E. A. A., Senderowitz, H., & Brodsky, J. L. (2019) · Protein Science · doi:10.1002/pro.3636 · Cited by 18

A novel fluorescent sensor for measurement of CFTR function by flow cytometry

Vijftigschild, L. A. W., van der Ent, C. K., & Beekman, J. M. (2013) · Cytometry Part A · doi:10.1002/cyto.a.22275 · Cited by 18

GM1 as Adjuvant of Innovative Therapies for Cystic Fibrosis Disease

Mancini, G., Loberto, N., Olioso, D., Dechecchi, M. C., Cabrini, G., Mauri, L., Bassi, R., Schiumarini, D., Chiricozzi, E., Lippi, G., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124486 · Cited by 17

Novel tricyclic pyrrolo-quinolines as pharmacological correctors of the mutant CFTR chloride channel

Renda, M., Barreca, M., Borrelli, A., Spanò, V., Montalbano, A., Raimondi, M. V., Bivacqua, R., Musante, I., Scudieri, P., Guidone, D., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-34440-0 · Cited by 18

Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms

Cao, L., Wu, Y., Gong, Y., & Zhou, Q. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116120 · Cited by 18

Serum and Glucocorticoid-Inducible Kinase1 Increases Plasma Membrane wt-CFTR in Human Airway Epithelial Cells by Inhibiting Its Endocytic Retrieval

Bomberger, J. M., Coutermarsh, B., Barnaby, R., Sato, J. D., Chapline, M. C., & Stanton, B. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089599 · Cited by 17

The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis

Bergougnoux, A., Petit, A., Knabe, L., Bribes, E., Chiron, R., Sario, A. D., Claustres, M., Molinari, N., Vachier, I., Taulan‐Cadars, M., et al. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.05.002 · Cited by 17

Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure

Cabrini, G. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0372-6 · Cited by 17

Variable Responses to CFTR Correctors in vitro: Estimating the Design Effect in Precision Medicine

Matthes, E., Goepp, J., Martini, C., Shan, J., Liao, J., Thomas, D. Y., & Hanrahan, J. W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01490 · Cited by 17

Pharmacoproteomics pinpoints HSP70 interaction for correction of the most frequent Wilson disease-causing mutant of ATP7B

Concilli, M., Petruzzelli, R., Parisi, S., Catalano, F., Sirci, F., Napolitano, F., Renda, M., Galietta, L. J. V., di Bernardo, D., & Polishchuk, R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006648117 · Cited by 17

Structure basis of CFTR folding, function and pharmacology

Hwang, T., Braakman, I., van der Sluijs, P., & Callebaut, I. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.09.010 · Cited by 16

New and Emerging Treatments for Cystic Fibrosis

Barry, P. J., & Jones, A. M. (2015) · Drugs · doi:10.1007/s40265-015-0424-8 · Cited by 17

ATP-Binding Cassette and Solute Carrier Transporters: Understanding Their Mechanisms and Drug Modulation Through Structural and Modeling Approaches

Elbahnsi, A., Dudás, B., Callebaut, I., Hinzpeter, A., & Miteva, M. A. (2024) · Pharmaceuticals · doi:10.3390/ph17121602 · Cited by 19

Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators

Tümmler, B., Pallenberg, S. T., Dittrich, A., Graeber, S. Y., Naehrlich, L., Sommerburg, O., & Mall, M. A. (2025) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-025-00194-0 · Cited by 20

Modifying disease in cystic fibrosis

Ong, T., & Ramsey, B. W. (2013) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328365ab5f · Cited by 16

Cystic fibrosis

Fajac, I., & Burgel, P. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104169 · Cited by 16

Computational analysis of long-range allosteric communications in CFTR

Ayca, E., Altintel, B., Levanon, N. L., Ben‐Tal, N., Haliloǧlu, T., & Lewinson, O. (2023) · eLife · doi:10.7554/elife.88659.3 · Cited by 17

Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor

Ferreira, F. C., Buarque, C. D., & Lopes‐Pacheco, M. (2024) · Molecules · doi:10.3390/molecules29040821 · Cited by 17

Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator correctors VX-445 and VX-121

Kolski‐Andreaco, A., Taiclet, S. N., Myerburg, M. M., Sembrat, J., Bridges, R. J., Straub, A. C., Wills, Z. P., Butterworth, M. B., & Devor, D. C. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176328 · Cited by 16

Unraveling the Mechanism of Action, Binding Sites, and Therapeutic Advances of CFTR Modulators: A Narrative Review

Baroni, D. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47020119 · Cited by 17

Increased efficacy of VX ‐809 in different cellular systems results from an early stabilization effect of F508del‐ CFTR

Farinha, C. M., Sousa, M., Canato, S., Schmidt, A., Uliyakina, I., & Amaral, M. D. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.152 · Cited by 43

Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function

Arora, K., & Naren, A. P. (2016) · Current Drug Targets · doi:10.2174/1389450117666151209114343 · Cited by 11

Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors

Amico, G., Brandas, C., Morán, Ó., & Baroni, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215463 · Cited by 27

Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment

Capurro, V., Tomati, V., Sondo, E., Renda, M., Borrelli, A., Pastorino, C., Guidone, D., Venturini, A., Giraudo, A., Bertozzi, S. M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105262 · Cited by 72

Revertants, Low Temperature, and Correctors Reveal the Mechanism of F508del-CFTR Rescue by VX-809 and Suggest Multiple Agents for Full Correction

Farinha, C. M., King-Underwood, J., Sousa, M., Correia, A. R., Henriques, B. J., Roxo‐Rosa, M., Paula, A. C. D., Williams, J. P., Hirst, S., Gomes, C. M., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.06.004 · Cited by 164